Lv8
6640 积分 2023-02-21 加入
盐酸环丙沙星合成与结晶过程的研究
10个月前
已完结
麝香系统溶液结晶溶剂选择的研究
10个月前
已完结
FIGO-Ⅰ期卵巢透明细胞癌患者预后分析
1年前
已完结
Ⅰ期卵巢透明细胞癌患者临床病理特点及预后分析——北京协和医院12年临床资料回顾性分析
1年前
已完结
基于GC-MS探讨肝脏再生代谢变化规律及相关代谢标志物的研究
1年前
已完结
Design, synthesis and antitumor evaluation of ATP dual-mimic 2,4-diarylaminopyrimidine and aminoindazole conjugates as potent anaplastic lymphoma kinase inhibitors
1年前
已完结
Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel ALK inhibitors
1年前
已完结
The synthesis and evaluation of sulfonamide derivatives target EGFR790M/L858R mutations and ALK rearrangement as anticancer agents
1年前
已完结
Identification of highly potent 2,4‐diarylaminopyrimidine analogs of a typical piperidinyl‐4‐ol moiety as promising antitumor ALK inhibitors
1年前
已完结
Abstract 3519: EVOLVE104, a differentiated T cell engager targeting the novel antigen ULBP2/5/6, exhibits potent preclinical efficacy for the treatment of squamous tumors
4小时前
待审核
Abstract 342: First-in-class click chemistry-based pre-targeting of CEACAM5 tumor antigen selectively activates an MMAE payload at tumors
14天前
已采纳
Data from The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
16天前
已采纳
Abstract 7286: A first-in-class αPD-1/αVEGF/IL-2v tri-specific fusion protein demonstrates promising anti-tumor efficacy in immune checkpoint inhibitor-resistant tumor models
16天前
已采纳
Abstract PR10: Tri-complex inhibitors of the oncogenic, GTP-bound form of KRASG12C overcome RTK-mediated escape mechanisms and drive tumor regressions in vivo
18天前
已采纳
Abstract P3-08-19: Preliminary results from PIKture-01, a First-in-Human Study of OKI-219, a mutant selective inhibitor of PI3Kα-H1047R, in mutant selected solid tumors including breast cancer
29天前
已采纳
Abstract 2656: The selective IKZF2 molecular glue degrader, PVTX-405, counters Treg immune suppression,shows significant tumor growth delay as single agent and synergistic response with immune checkpoint therapies (ICTs)
29天前
已采纳
Abstract 1721: TAC-001, a toll-like receptor 9 (TLR9) agonist antibody conjugate targeting B cells, promotes anti-tumor immunity and favorable safety profile following systemic administration in preclinical models
1个月前
已采纳
Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells
1个月前
已采纳
Abstract LB428: An orally bioavailable RIPTAC™ therapeutic for p53 Y220C mutant tumors
1个月前
已采纳
皖公网安备34019202002308
